

# Clarke, Modet & Cº

COLOMBIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

P-3193



No. 11-179296-00011-0000

Fecha: 2015-03-19 15:15:03 Dep. 2020 DIR.NUEVASCR  
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI  
Act. 608 MODIFICASOLICIT Folios: 55

SUPERINTENDENCIA DE INDUSTRIA Y CC  
DIVISION DE NUEVAS CREACIONES  
E. S. D.

Re: Expediente No. 11-179.296

Solicitud de patente a nombre de AGIOS PHARMACEUTICALS- INC.

Yo, SILVANA MARIA LÓPEZ DÍAZ identificada como aparece al pie de mi firma, domiciliada en la Cra. 11 No. 86-53 Piso 6, obrando como apoderada de la sociedad AGIOS PHARMACEUTICALS- INC., domiciliada en Massachusets, Estados Unidos, solicitante de la patente de la referencia, me permito informar lo siguiente:

Con fundamento en la facultad que confiere el artículo 34 de la Decisión 486 al solicitante para modificar la solicitud de patente en cualquier momento del trámite, incluso después de concedida, como ocurre en el presente caso, presento junto con este memorial un nuevo pliego reivindicatorio que comprende un total de 43 reivindicaciones, en donde se han adicionado las nuevas reivindicaciones 20 a 42, las cuales reportan nuevos compuestos que están cobijados por aquellos compuestos reportados en la reivindicación concedida 19 y por tanto, a su vez se encuentran debidamente soportados en el capítulo descriptivo de la presente solicitud, lo que implica que no se está incurriendo en ampliación de materia.

De ésta manera, se le solicita al presente Despacho, tener en consideración este nuevo pliego reivindicatorio, para lo cual adicionalmente se adjunta, la copia del recibo de pago por concepto de 23 reivindicaciones adicionales y por modificación voluntaria.

Señor Superintendente,

  
SILVANA MARIA LÓPEZ DÍAZ

C.C. 22.468.787 de Barranquilla

T.P 147463 del CSJ

notificaciones@clarkemodet.com.co

11/55

# **Clarke, Modet & Cº**

---

COLOMBIA

## **ANEXOS**

- Nuevo pliego reivindicatorio compuesto por 43 reivindicaciones
- Copia de recibo de pago por concepto de modificación voluntaria, por un valor de \$ 132.000.
- Copia de recibo de pago por concepto de 23 reivindicaciones adicionales, por un valor de \$ 736.000.

**DIRECCIÓN DE NUEVAS CREACIONES**  
**MODIFICACIONES Y/O CORRECCIONES**

**1. Identificación del Trámite**

☐ Error material

☒ Modificación a una Solicitud en trámite

☒ Patente de Invención

☐ Patente de Modelo de Utilidad

☐ Registro de Diseño Industrial

☐ Esquema de Trazado de Circuitos Integrados

**2. Datos del solicitante**

Persona Natural ☐

Persona Jurídica ☒

**AGIOS PHARMACEUTICALS, INC.**

Nombre o denominación / Nombre o razón social completa

Nombre representante legal

Tipo de empresa

Micro ☐

Pequeña ☐

Mediana ☐

Otra ☐

Documento de identificación:

☐ C.C.

☐ C.E.

☐ NIT

☐ Otro

Número

|                                   |                                   |                      |
|-----------------------------------|-----------------------------------|----------------------|
| Nacionalidad/País de constitución | Dirección y domicilio del titular | Ciudad               |
| Estados Unidos de América         | 38 Sidney Street Cambridge,       | Massachusetts 02139, |
| Dirección electrónica             | No. Fax                           | Número telefónico    |

☐

Autorizo expresamente a la Superintendencia de Industria y Comercio para que todas las comunicaciones sean enviadas a través de la dirección de correo electrónico

**3. Datos del apoderado:**

**SILVANA MARIA LÓPEZ DÍAZ**

**C.C. 22.468.787**

**147463 CSJ**

Apellidos y Nombre

Documento de identificación

Tarjeta profesional

|                                                     |         |                   |
|-----------------------------------------------------|---------|-------------------|
| Dirección y domicilio                               |         | Ciudad            |
| Carrera 11 No. 86-53, Piso 6, Bogotá D.C., Colombia |         | Bogotá D.C.       |
| Dirección electrónica                               | No. Fax | Número telefónico |
| <u>notificaciones@clarkemodet.com.co</u>            | 6350824 | 6181088           |

En caso de haber presentado poder general para asuntos que se adelanten ante la Delegatura de Propiedad Industrial, sirvase indicar el número de su radicación o protocolo de poder general

4. Datos del trámite :

Corrección:

Expediente No. **11-179.296**

Aparece \_\_\_\_\_

Debe ser \_\_\_\_\_

Modificación:

☐

Presentación Solicitud Divisional.

☒

Modificación al capítulo descriptivo.

Presento junto con este memorial un nuevo pliego reivindicatorio que comprende un total de 43 reivindicaciones, en donde se han adicionado las nuevas reivindicaciones 20 a 42.

☐

Modificación al capítulo Reivindicatorio

☐

Modificación al resumen.

☐

Modificación a los dibujos.

Modificación Solicitud

5. Anexos

☒

Comprobante de pago de la tasa para la presentación de la corrección y/o modificación

Poder, si fuere el caso.

☒

Documento que contiene las modificaciones o correcciones

☐

Copia de la solicitud y sus anexos en formato magnético.

6. Firma

**SILVANA MARIA LOPEZ DIAZ**

C.C. 22.468.787 de Barranquilla

T.P 147463 del CSJ

notificaciones@clarkemodet.com.co

## SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

- / -

**Industria y Comercio**  
SUPERINTENDENCIA

## RECIBO DE CAJA

**No. 15 - 0030681**

Bogotá D.C., Marzo 16 de 2015 - 15:02:21

RECIBIDO DE : CLARKE MODET

NI 830.008.643

RE

## \*\*\* Soporte del Pago \*\*\*

| TIPO PAGO    | BANCO     | CUENTA | No. PAGO   | FECHA PAGO | VR. PAGO   |
|--------------|-----------|--------|------------|------------|------------|
| RECIBO DE CA | 999999999 | 8845   | 22/01/2015 |            | 185.000.00 |
| RECIBO DE CA | 999999999 | 8870   | 22/01/2015 |            | 530.000.00 |
| RECIBO DE CA | 999999999 | 8940   | 22/01/2015 |            | 509.000.00 |

## \*\*\* Conceptos Pagados \*\*\*

| CANT. | RENTISTICO                                       | CONCEPTO                                                 | Vr.UNDITARIO | Vr.CONCEPTO         |
|-------|--------------------------------------------------|----------------------------------------------------------|--------------|---------------------|
| 1     | 50005-01-03 CAMBIO DE MODALIDAD Y MODIFICACIONES | EN CREACION CORRECCION A SOLICITUD EN TRAMITE / MODIFICA | 132.000.00   | 132.000.00          |
|       |                                                  |                                                          |              | <b>\$132.000.00</b> |

SON: \*\*CIENTO TREINTA Y DOS MIL PESOS MONEDA CORRIENTE\*\*\*

Responsable: \_\_\_\_\_

Recibo de Caja Aplicado al Expediente No. \_\_\_\_\_

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

**No. 11-179296- -00011-0000**Fecha: 2015-03-19 15:15:03 Dep. 2020 DIR.NUEVASCR  
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI  
Act. 608 MODIFICASOLICIT Folios: 55

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C. - Colombia

Web: [www.sic.gov.co](http://www.sic.gov.co) e-mail: [info@sic.gov.co](mailto:info@sic.gov.co) Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

, Marzo 16 de 2015 - 15:02:27

4

## SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

- / -



Industria y Comercio

SUPERINTENDENCIA

## RECIBO DE CAJA

No. 15 - 0032293

Bogotá D.C., Marzo 19 de 2015 - 15:08:16

RECIBIDO DE : CLARKE MODET

NI 830.008.643

RE

## \*\*\* Soporte del Pago \*\*\*

| TIPO PAGO    | BANCO     | CUENTA | No. PAGO   | FECHA PAGO | VR PAGO    |
|--------------|-----------|--------|------------|------------|------------|
| RECIBO DE CA | 999999999 | 8871   | 22/01/2015 |            | 530.000.00 |
| RECIBO DE CA | 999999999 | 8910   | 22/01/2015 |            | 218.000.00 |

## \*\*\* Conceptos Pagados \*\*\*

| CANT. RENTISTICO           | CONCEPTO                                                        | Vr.UNDITARIO | Vr.CONCEPTO  |
|----------------------------|-----------------------------------------------------------------|--------------|--------------|
| 23 50005-01-01 SOLICITUDES | 1607 REIVINDICACION PATENTE UNITARIA<br>ADICIONAL A LAS 10 INIC | 32.000.00    | 736.000.00   |
|                            |                                                                 |              | \$736.000.00 |

SON: \*\*SETECIENTOS TREINTA Y SEIS MIL PESOS MONEDA CORRIENTE\*\*\*

Responsable:

Recibo de Caja Aplicado al Expediente No. \_\_\_\_\_

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 11-179296- -00011-0000

Fecha: 2015-03-19 15:15:03 Dep. 2020 DIR.NUEVASCR  
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI  
Act. 608 MODIFICASOLICIT Folios: 55


Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mail: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

, Marzo 19 de 2015 - 15:08:17

## REIVINDICACIONES

1. Un compuesto de la fórmula (I)



o una sal del mismo farmacéuticamente aceptable, caracterizado porque

- W, X, Y y Z son cada uno independientemente seleccionados a partir de CH o N;
- D y D¹ son independientemente seleccionados a partir de un enlace o NR<sup>b</sup>;
- A es quinolinilo opcionalmente sustituido;
- L es un enlace, -C(O)-, -(CR<sup>c</sup>R<sup>g</sup>)<sub>m</sub>-, -OC(O)-, -(CR<sup>c</sup>R<sup>g</sup>)<sub>m</sub>-OC(O)-, -(CR<sup>c</sup>R<sup>g</sup>)<sub>m</sub>-C(O)-, -NR<sup>b</sup>C(S)-, o -NR<sup>b</sup>C(O)-;
- R¹ se selecciona a partir de C1-C12 alquilo, C3-C12 cicloalquilo, arilo, heteroarilo de 4 a 14 miembros, y heterociclilo de 3 a 14 miembros; cada uno de los cuales es sustituido con 0-5 incidencias de R<sup>d</sup>;
- cada R³ se selecciona independientemente a partir de halo, C1-C12 haloalquilo, C1-C12 alquilo, hidroxilo y -OR<sup>a</sup> o dos R³ adyacentes tomados junto con los átomos de carbono a los cuales están unidos, forman un ciclilo opcionalmente sustituido;
- cada R<sup>a</sup> se selecciona independientemente a partir de C1-C12 alquilo, acilo, C1-C12 hidroxialquilo y C1-C12 haloalquilo;
- cada R<sup>b</sup> se selecciona independientemente a partir de hidrógeno y C1-C12 alquilo;
- cada R<sup>c</sup> se selecciona independientemente a partir de hidrógeno, halo, C1-C12 alquilo, C1-C12 alcoxi y C1-C12 haloalcoxi o dos R<sup>c</sup> tomados junto con los átomos de carbono a los cuales están unidos, forman un C3-C12 cicloalquilo opcionalmente sustituido;

- cada  $R^d$  se selecciona independientemente a partir de halo, C1-C12 haloalquilo, C1-C12 haloalcoxi, C1-C12 alquilo, C2-C12 alquinilo, nitro, ciano, hidroxilo,  $-C(O)R^a$ ,  $-OC(O)R^a$ ,  $-C(O)OR^a$ ,  $-SR^a$ ,  $-NR^aR^b$  y  $-OR^a$ , o dos  $R^d$  tomados junto con los átomos de carbono a los cuales están unidos, forman un heterociclilo de 3 a 14 miembros opcionalmente sustituido;

n es 0, 1, o 2;

m es 1, 2 o 3;

h es 0, 1, 2; y

g es 0, 1 o 2.

2. El compuesto de conformidad con la reivindicación 1, caracterizado porque h es 1 y g es 1.

3. El compuesto de conformidad con la reivindicación 2, o una sal farmacéuticamente aceptable del mismo, caracterizado porque W, X, Y y Z son CH.

4. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 3, o una sal farmacéuticamente aceptable del mismo, caracterizado porque D es  $NR^b$  y  $D^1$  es un enlace.

5. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 4, o una sal farmacéuticamente aceptable del mismo, caracterizado porque  $R^b$  es H, metilo o etilo.

6. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es un enlace y R1 es alquilo, arilo o heteroarilo sustituido con 0 – 5 incidencias de  $R^d$ .

7. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es –

$(CR^cR^g)_m$ - y R1 es cicloalquilo, arilo, heteroarilo o heterociclilo con 0 – 5 incidencias de  $R^d$ .

8. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es  $-NR^bC(O)-$ ,  $R^b$  es hidrógeno y R1 es arilo sustituido con 0 – 5 incidencias de  $R^d$ .

9. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es  $-(CR^cR^g)_m-C(O)-$  y R1 es cicloalquilo, arilo o heteroarilo sustituido con 0 – 5 incidencias de  $R^d$ .

10. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es  $-C(O)-$  y R1 es alquilo, arilo o heteroarilo sustituido con 0 – 5 incidencias de  $R^d$ .


11. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es  $-OC(O)-$  y R1 es alquilo, arilo o heterociclilo sustituido con 0 – 5 incidencias de  $R^d$ .

12. El compuesto de conformidad con cualquiera de las reivindicaciones 1 a 5, o una sal farmacéuticamente aceptable del mismo, caracterizado porque L es  $-(CR^cR^g)_m-OC(O)-$  y R1 es heterociclilo o cicloalquilo sustituido con 0 – 5 incidencias de  $R^d$ .

13. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 12 o una sal farmacéuticamente aceptable del mismo, caracterizado porque n es 0.


14. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 12 o una sal farmacéuticamente aceptable del mismo, caracterizado porque n es 1 y  $R^3$  es  $CH_3$ ,  $CH_2CH_3$ ,  $OCH_3$ ,  $OCH_2CH_3$ , OH, F, Cl, o  $CF_3$ .

15. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 14 o una sal farmacéuticamente aceptable del mismo, caracterizado porque el compuesto es un compuesto de la fórmula (Id):



(Id).























16. El compuesto de conformidad con cualquiera de las reivindicaciones 1 – 15 o una sal farmacéuticamente aceptable del mismo, caracterizado porque A es:

























17. El compuesto de conformidad con la reivindicación 1 caracterizado porque el compuesto se selecciona del grupo que consiste de:























|  |  |
|--|--|
|  |  |
|  |  |
|  |  |
|  |  |


9





















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |





















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

11



















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |







































|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |


|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|    |    |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |



















15



















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|   |    |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |



















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |



















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |





|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |



















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |


|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |


|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |







|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|   |   |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |














|  |  |
|--|--|
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |























20


|  |  |
|--|--|
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |


O una sal farmacéuticamente aceptable del mismo.


18. El compuesto de conformidad con la reivindicación 1, caracterizado porque el compuesto se selecciona del grupo que consiste de:























|  |  |
|--|--|
|  |  |
|  |  |
|  |  |





















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|    |    |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
















|                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|    |    |
|    |    |
|    |    |
|    |    |
|  |  |

O una sal farmacéuticamente aceptable del mismo.


19. El compuesto de conformidad con la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en donde el compuesto se selecciona del grupo que consiste de:




5




20. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




21. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




22. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




23. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula




24. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




25. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:



26. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




27. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




52


28. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




29. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




30. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




31. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:



32. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




33. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




53


34. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




35. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




36. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




37. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




38. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:



39. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




40. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:




54

41. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:



42. Un compuesto de acuerdo con la reivindicación 19, que tiene la fórmula:



43. Una composición farmacéutica que comprende un compuesto de conformidad con cualquiera de las reivindicaciones 1 – 42, o una sal farmacéuticamente aceptable de estos.

55